Trials / Completed
CompletedNCT05578391
Passive Immunotherapy In Patients With SARS CoV-2
PHASE II Clinical Trial Randomized And Controlled To Assess Need Of Oxygen On Day 14 After Administration Of Passive Immunotherapy In Patients Infected By SARS-CoV-2 With Risks Factors For Severe Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Fundacin Biomedica Galicia Sur · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Plasma from convalescent individuals (convalescent plasma, CP) has been used for more than a hundred years for the treatment of infectious diseases. Among patients with COVID-19, it has been used first, in patients with severe infection. Although it is a safe treatment, it has not been possible to demonstrate a reduction in mortality in cases of acute respiratory distress syndrome. The objective of the clinical trial is to evaluate the efficacy and safety of the early use (less than 5 days of symptoms) of CP in patients infected with SARS-CoV-2 with risk factors for severe disease. The primary efficacy endpoint was the proportion of patients requiring oxygen therapy to maintain saturation \>93% on day 14. Secondary objectives included, evaluation of the safety of the treatment, measured as the appearance of some adverse event related to the CP infusion; the evolution of COVID-19 symptoms and WHO progression scale status at day 14 and 28 after inclusion; the need for hospitalization due to progression of COVID-19. COVID-19 progression was considered as worsening of respiratory symptoms requiring oxygen therapy at some point. Finally, death from any cause was evaluated at 28 days, after inclusion in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Convalescent plasma | Admistration of one unit of convalescent plasma |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2020-12-31
- Completion
- 2021-03-31
- First posted
- 2022-10-13
- Last updated
- 2022-10-13
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05578391. Inclusion in this directory is not an endorsement.